Esperion Therapeutics
ESPR
#6764
Rank
$0.61 B
Marketcap
$2.58
Share price
-4.83%
Change (1 day)
67.47%
Change (1 year)

P/S ratio for Esperion Therapeutics (ESPR)

P/S ratio as of March 2026 (TTM): 2.13

According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.44. At the end of 2025 the company had a P/S ratio of 1.76.

P/S ratio history for Esperion Therapeutics from 2013 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20251.7630.1%
20241.35-53.75%
20232.92-51.95%
20226.0856.69%
20213.8831.08%
20202.96-73.21%
201911.1
2018N/A
2017N/A
2016N/A
2015N/A
2014N/A
2013N/A

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.49 16.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
5.59 162.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Ultragenyx Pharmaceutical
RARE
3.31 55.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
9.69 354.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
7.54 253.41%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
3.48 63.38%๐Ÿ‡บ๐Ÿ‡ธ USA